Business Description
Relmada Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75955J4022
Total Employee Number:
17Description
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 35 | |||||
3-Year EPS without NRI Growth Rate | 34.3 | |||||
3-Year FCF Growth Rate | 30.8 | |||||
3-Year Book Growth Rate | -36.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.28 | |||||
9-Day RSI | 60.44 | |||||
14-Day RSI | 55.55 | |||||
3-1 Month Momentum % | 11.98 | |||||
6-1 Month Momentum % | 61.8 | |||||
12-1 Month Momentum % | 1080.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.25 | |||||
Quick Ratio | 18.25 | |||||
Cash Ratio | 18.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.6 | |||||
Shareholder Yield % | -22.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -83.37 | |||||
ROA % | -74.9 | |||||
ROIC % | -4841.38 | |||||
3-Year ROIIC % | -20348.41 | |||||
ROCE % | -84.24 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.34 | |||||
Price-to-Tangible-Book | 3.34 | |||||
EV-to-EBIT | -8.27 | |||||
EV-to-Forward-EBIT | -5.49 | |||||
EV-to-EBITDA | -8.27 | |||||
EV-to-Forward-Revenue | 0.53 | |||||
EV-to-FCF | -11.66 | |||||
| Price-to-Net-Current-Asset-Value | 3.34 | |||||
| Price-to-Net-Cash | 3.37 | |||||
Earnings Yield (Greenblatt) % | -12.09 | |||||
FCF Yield % | -5.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RLMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relmada Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.091 | ||
| Beta | 1.154 | ||
| 3-Year Sharpe Ratio | 0.87 | ||
| 3-Year Sortino Ratio | 1.94 | ||
| Volatility % | 144.1 | ||
| 14-Day RSI | 55.55 | ||
| 14-Day ATR ($) | 0.443028 | ||
| 20-Day SMA ($) | 6.497 | ||
| 12-1 Month Momentum % | 1080.33 | ||
| 52-Week Range ($) | 0.55 - 8 | ||
| Shares Outstanding (Mil) | 104.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relmada Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relmada Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 137 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 38 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 12:50 | 6.33 (-1.25%) | ||
| General meeting for 2026 | 2026-05-27 09:30 | 7.17 (+0.70%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 7.36 (+0.41%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.36 (+0.41%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 16:30 | 6.21 (-3.72%) | ||
| Annual report for 2025 | 2026-03-19 | 6.21 (-3.72%) |
Show
Entries
Relmada Therapeutics Inc Frequently Asked Questions
What is Relmada Therapeutics Inc(RLMD)'s stock price today?
The current price of RLMD is $6.98. The 52 week high of RLMD is $8.00 and 52 week low is $0.55.
When is next earnings date of Relmada Therapeutics Inc(RLMD)?
The next earnings date of Relmada Therapeutics Inc(RLMD) is 2026-08-07 Est..
Does Relmada Therapeutics Inc(RLMD) pay dividends? If so, how much?
Relmada Therapeutics Inc(RLMD) does not pay dividend.
Guru Commentaries on NAS:RLMD
No articles.
Press Release
Articles on Relmada Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers